Master protocols are helping drive a shift in drug development, transitioning the industry from traditional, standalone trial designs to integrated, evidence-generating platforms. Adoption of master protocols, including basket, umbrella, and platform trials, is accelerating as sponsors recognize the potential to make R&D faster and more efficient by assessing multiple hypotheses within a single study.
However, while such innovative designs are frequently discussed conceptually, less attention is given to the biostatistical considerations needed to execute them successfully in practice. Translating complex, adaptive designs into rigorous statistical practice introduces challenges, often causing the promise of master protocols to collide with practical and regulatory barriers. This white paper explores the gap between theory and execution, examining topics such as:
- The implications of using master protocols
- How to operationalize complex designs
- Practical considerations for biopharma teams
- Regulatory acceptance of Bayesian versus frequentist trial designs
- How early engagement with agencies overcomes concerns
FAQs
A master protocol is an overarching protocol that governs multiple clinical substudies within a single clinical trial framework. It specifies the overall study design and common requirements for how the research will be conducted and analyzed, while each substudy addresses a specific research question. This allows related research questions to be investigated within a coordinated structure rather than through separately designed, standalone studies.
The main types of master protocols are basket, umbrella, and platform trials.
- Basket trials evaluate a single treatment across different diseases or disease subtypes.
- Umbrella trials evaluate multiple treatments within a single disease.
- Platform trials evaluate multiple treatments within an ongoing framework that allows treatment arms to be added or removed according to prespecified rules.
A basket trial evaluates a single treatment across multiple diseases or patient populations, while an umbrella trial evaluates multiple treatments or approaches within a single disease or condition.
A basket trial evaluates a single treatment across different diseases or disease subtypes under one overarching protocol. For example, patients with lung cancer and patients with colorectal cancer may receive the same treatment because their tumors share a specific feature that the treatment targets. Each patient group, defined by its cancer diagnosis, is evaluated in a separate substudy within the same basket trial.
An umbrella trial evaluates multiple treatments within a single disease under one overarching protocol. For example, patients with lung cancer may receive different treatments based on genetic differences in their tumors. Each treatment is evaluated in a separate substudy within the same umbrella trial.
A basket trial evaluates a single treatment across different diseases or disease subtypes under one overarching protocol. For example, patients with lung cancer and patients with colorectal cancer may receive the same treatment because their tumors share a specific feature that the treatment targets. Each patient group, defined by its cancer diagnosis, is evaluated in a separate substudy within the same basket trial.
An umbrella trial evaluates multiple treatments within a single disease under one overarching protocol. For example, patients with lung cancer may receive different treatments based on genetic differences in their tumors. Each treatment is evaluated in a separate substudy within the same umbrella trial.
A platform trial evaluates multiple treatments under a single master protocol, allowing treatment arms to be added or removed over time according to prespecified rules as evidence emerges. For example, a lung cancer platform trial may add a new treatment arm alongside existing arms when new evidence supports evaluating another therapy. A treatment arm may also stop enrolling patients if its treatment shows insufficient benefit. The trial is therefore not limited to only the treatment arms included when it began.
Master protocols can help sponsors evaluate multiple research questions within a single coordinated framework, potentially improving efficiency compared with conducting separate standalone trials. By using common study infrastructure and, where appropriate, shared screening processes or control groups, master protocols may reduce duplication, make more efficient use of patients and trial sites, and streamline study operations. They can also support more coordinated evidence generation across multiple treatments, diseases, or patient populations.
Master protocols can be more complex to design and operate than traditional standalone trials. They require careful planning and coordination across multiple substudies, sites, treatment arms, and patient populations, as applicable. They can also introduce statistical complexities, including decisions about analysis methods, shared control groups, and how data are evaluated across substudies. Regulatory considerations may add further complexity, particularly when a master protocol includes multiple investigational treatments or evolves over time.
Request a Proposal
Share This
